The state of Rhode Island has settled opioid claims against generic pharmaceutical manufacturer Teva Pharmaceutical Industries Ltd. just before its lawyers were set to begin opening statements to jurors on Monday.

Rhode Island Attorney General Peter Neronha said the Teva agreement and another settlement with Allergan together totaled about $107 million in value. That includes $28.5 million in cash: Teva will provide $21 million, while $7.5 million will come from Allergan. Both settlements also provide 1 million nasal sprays of Naxloxone, used to treat opioid overdoses, over the next decade.